Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Cypherpunk Technologies Inc. (CYPH) vs PureTech Health PLC Sponsored ADR (PRTCY)

Cypherpunk Technologies Inc. and PureTech Health PLC Sponsored ADR are both Biotechnology companies. Cypherpunk Technologies Inc. and PureTech Health PLC Sponsored ADR are of similar size ($440.8M and $424.0M). PureTech Health PLC Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Cypherpunk Technologies Inc. trades at 7.0×. PureTech Health PLC Sponsored ADR grew revenue faster over the last twelve months: 28.5% against 0.00%. Cypherpunk Technologies Inc. has the higher net margin (0.00% vs −199.4%) and the lower return on invested capital (−8.44% vs 0.00%). Across the 11 metrics below, PureTech Health PLC Sponsored ADR leads on 6 and Cypherpunk Technologies Inc. on 5.

Valuation

Metric CYPH PRTCY Biotechnology median
P/E 6.98 n/m 7.88
P/S 506.29 n/m 11.47
P/B 5.45 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.78 0.74
EV/Sales 501.20 (8.76) 10.73
Earnings yield 14.32% (1.40%) (28.84%)
Free cash flow yield (2.77%) 0.00% (23.03%)

Profitability

Metric CYPH PRTCY Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% (199.36%) 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (1.21%) 0.00% (57.72%)
Return on assets (1.08%) 0.00% (49.22%)
Return on invested capital (8.44%) 0.00% 0.00%

Growth

Metric CYPH PRTCY Biotechnology median
Revenue growth (TTM) 0.00% 28.48% 5.64%
EPS growth (last fiscal year) 103.87% (2,277.05%) —
Revenue growth, 5-year CAGR — (23.16%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CYPH PRTCY Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 79.19 6.59 4.73
Net debt to EBITDA 0.34 3.03 0.96

Dividend

Metric CYPH PRTCY Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CYPH PRTCY Biotechnology median
Market cap 440.76m 424.00m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack